What is MGB Biopharma?
MGB Biopharma is a specialized biotechnology enterprise dedicated to the discovery and development of a new class of anti-infective medicines. At the core of its innovation is the Minor Groove Binder (MGB) compound platform, which enables the creation of small molecules with potent antibacterial activity against both susceptible and resistant bacterial strains. The company's flagship candidate, MGB-BP-3, is currently positioned to address the urgent medical need for effective treatments against Clostridium difficile infections. By targeting the minor groove of DNA, MGB Biopharma offers a distinct mechanism of action that differentiates its portfolio from traditional antibiotic therapies, positioning the firm as a key player in the fight against multi-drug resistant pathogens.
How much funding has MGB Biopharma raised?
MGB Biopharma has raised a total of $7.4M across 2 funding rounds:
Unspecified
$6.4M
Unspecified
$1M
Unspecified (2014): $6.4M with participation from TRI Cap
Unspecified (2017): $1M led by Archangel Investors Ltd and The TRICAPITAL Syndicate
Key Investors in MGB Biopharma
TRI Cap
Tweed Renaissance Investors Capital (TRI Cap) is a business angel syndicate based in the Scottish Borders, with the intention of investing in growth businesses in the Borders and beyond.
Archangel Investors Ltd
A prominent investment group focused on supporting high-growth technology and life science ventures through early-stage and follow-on capital.
The TRICAPITAL Syndicate
A specialized syndicate of experienced business leaders providing strategic capital and operational expertise to emerging enterprises in the life sciences sector.
What's next for MGB Biopharma?
Looking ahead, MGB Biopharma is poised to leverage its recent capital to finalize clinical trials and navigate the complex regulatory pathways required for market entry. The strategic focus remains on the successful commercialization of MGB-BP-3, which has demonstrated potential superiority over existing standard-of-care treatments. As the company scales its operations, it will likely prioritize partnerships with larger pharmaceutical entities to facilitate global distribution and manufacturing. The ongoing commitment to scientific rigor and the expansion of its intellectual property portfolio will be essential as the firm seeks to establish a new paradigm in antibacterial therapy, ultimately aiming to mitigate the long-term risks associated with antibiotic resistance in clinical settings.
See full MGB Biopharma company page
